Market closedNon-fractional
Day One Biopharmaceuticals/DAWN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Ticker
DAWN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Brisbane, United States
Employees
174
Website
dayonebio.com
DAWN Metrics
BasicAdvanced
$1.2B
Market cap
-
P/E ratio
-$2.50
EPS
-1.45
Beta
-
Dividend rate
Price and volume
Market cap
$1.2B
Beta
-1.45
Financial strength
Current ratio
10.926
Quick ratio
10.655
Total debt to equity
0.101
Management effectiveness
Return on assets (TTM)
-42.67%
Return on equity (TTM)
-69.97%
Valuation
Price to book
3.98
Price to tangible book (TTM)
3.98
Price to free cash flow (TTM)
-6.46
Growth
Earnings per share change (TTM)
9.94%
3-year earnings per share growth
-33.25%
What the Analysts think about DAWN
Analyst Ratings
Majority rating from 11 analysts.
DAWN Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$62M
14.50%
Profit margin
0.00%
NaN%
DAWN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.61
-$0.54
-$0.64
-$0.72
-
Expected
-$0.61
-$0.60
-$0.58
-$0.66
-$0.62
Surprise
-0.02%
-10.35%
9.71%
8.54%
-
DAWN News
AllArticlesVideos
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
GlobeNewsWire·2 weeks ago
Day One Announces Sale of Priority Review Voucher for $108 Million
GlobeNewsWire·1 month ago
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Day One Biopharmaceuticals stock?
Day One Biopharmaceuticals (DAWN) has a market cap of $1.2B as of July 05, 2024.
What is the P/E ratio for Day One Biopharmaceuticals stock?
The price to earnings (P/E) ratio for Day One Biopharmaceuticals (DAWN) stock is 0 as of July 05, 2024.
Does Day One Biopharmaceuticals stock pay dividends?
No, Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Day One Biopharmaceuticals dividend payment date?
Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders.
What is the beta indicator for Day One Biopharmaceuticals?
Day One Biopharmaceuticals (DAWN) has a beta rating of -1.45. This means that it has an inverse relation to market volatility.
Buy or sell Day One Biopharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.